Plain-English translation of NCT04305717 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing Remote Dielectric Sensing (ReDS), a non-invasive device that measures fluid buildup in your lungs using electromagnetic energy. If you're in the treatment group, your doctor will see daily ReDS measurements and use them to guide decisions about when you're ready to go home and what medications you need. The goal is to help doctors catch fluid buildup earlier and prevent you from being readmitted to the hospital.
Many heart failure patients are readmitted to the hospital shortly after discharge because doctors can't reliably tell when extra fluid is still present in the lungs just by looking at symptoms or standard tests. This device offers a new, non-invasive way to measure lung fluid that could help doctors make better discharge decisions and prevent these readmissions.
You likely qualify if…
You likely don't qualify if…
You will be hospitalized and randomly assigned to one of two groups. In both groups, you'll have daily measurements taken with the ReDS device while you're in the hospital. If you're in the treatment group, your doctors will see these measurements and use them to guide decisions about your medications and discharge timing. If you're in the standard care group, the measurements will be taken but hidden from your doctors, who will manage your care as they normally would. Your participation will continue through your hospital stay and into the early discharge period, which is when patients are most at risk of readmission.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States